GTC Biotherapeutics, Inc. ("GTC", OTCBB: GTCB.OB) announced today that it has signed a definitive agreement whereby the Company has regained US commercialization rights to ATryn from Lundbeck, Inc., a wholly owned subsidiary of H. Lundbeck A/S in Denmark (Copenhagen Stock Exchange: LUN)... 
More...
More...